Editas Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
EDIT$2.75+7.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(amounts in thousands, except per share and share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration and other research and development revenues | $40,520 | $32,314 |
| Operating expenses: | ||
| Research and development | 89,953 | 199,247 |
| General and administrative | 49,903 | 71,987 |
| Restructuring and impairment charges | 60,674 | 12,232 |
| Total operating expenses | 200,530 | 283,466 |
| Operating loss | (160,010) | (251,152) |
| Other income (expense), net: | ||
| Interest expense related to sale of future revenues | (6,171) | (2,190) |
| Interest income, net | 8,310 | 16,252 |
| Other expense, net | (2,189) | (3) |
| Total other income (expense), net | (50) | 14,059 |
| Net loss | $(160,060) | $(237,093) |
| Net loss per share, basic and diluted | $(1.80) | $(2.88) |
| Weighted-average common shares outstanding, basic and diluted | 88,745,908 | 82,338,220 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.